Ramipril TAD 1,25 mg tabletes Letonia - letón - Zāļu valsts aģentūra

ramipril tad 1,25 mg tabletes

tad pharma gmbh, germany - ramiprils - tabletes - 1,25 mg

Ramipril TAD 5 mg tabletes Letonia - letón - Zāļu valsts aģentūra

ramipril tad 5 mg tabletes

tad pharma gmbh, germany - ramiprils - tablete - 5 mg

Ramipril TAD 2,5 mg tabletes Letonia - letón - Zāļu valsts aģentūra

ramipril tad 2,5 mg tabletes

tad pharma gmbh, germany - ramiprils - tablete - 2,5 mg

Ramipril TAD 10 mg tabletes Letonia - letón - Zāļu valsts aģentūra

ramipril tad 10 mg tabletes

tad pharma gmbh, germany - ramiprils - tablete - 10 mg

Ramipril Actavis 10 mg tabletes Letonia - letón - Zāļu valsts aģentūra

ramipril actavis 10 mg tabletes

teva b.v., netherlands - ramiprils - tablete - 10 mg

Ramlon 2,5 mg/2,5 mg cietās kapsulas Letonia - letón - Zāļu valsts aģentūra

ramlon 2,5 mg/2,5 mg cietās kapsulas

egis pharmaceuticals plc, hungary - ramiprilum, amlodipinum - kapsula, cietā - 2,5 mg/2,5 mg

Maxitrol acu pilieni, suspensija Letonia - letón - Zāļu valsts aģentūra

maxitrol acu pilieni, suspensija

novartis baltics, sia, latvia - dexamethasonum, neomycini sulfas, polymyxini b sulfas - acu pilieni, suspensija - 1 mg/3500sv/6000 sv/ml

Entresto Unión Europea - letón - EMA (European Medicines Agency)

entresto

novartis europharm limited - sacubitril, valsartan - sirdskaite - angiotensīna ii antagonisti, citas kombinācijas, līdzekļi, kas iedarbojas uz renin-angiotensīna sistēmu - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Neparvis Unión Europea - letón - EMA (European Medicines Agency)

neparvis

novartis europharm limited - sacubitril, valsartan - sirdskaite - agents, kas iedarbojas uz renīna-angiotenzīna sistēmu - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.